ABSTRACT
As other European countries, France is experiencing a resurgence of pertussis in 2024. Between 1 January and 31 May 2024, 5,616 (24.9%) positive Bordetella pertussis qPCR tests were identified, following a 3-year period of almost null incidence. Of 67 cultured and whole genome sequenced B. pertussis isolates, 66 produced pertactin and 56 produced FIM2, in contrast to pre-COVID-19 years. One isolate of genotype Bp-AgST4 was resistant to macrolides. Pertussis resurgence may favour isolates that produce FIM2 and pertactin.
Subject(s)
Anti-Bacterial Agents , Bordetella pertussis , Macrolides , Whooping Cough , Bordetella pertussis/genetics , Bordetella pertussis/isolation & purification , Bordetella pertussis/drug effects , Humans , France/epidemiology , Macrolides/pharmacology , Whooping Cough/epidemiology , Whooping Cough/microbiology , Anti-Bacterial Agents/pharmacology , Drug Resistance, Bacterial , Microbial Sensitivity Tests , Bacterial Outer Membrane Proteins/genetics , Whole Genome Sequencing , Virulence Factors, Bordetella/genetics , Genotype , Adult , Child , Incidence , Child, PreschoolABSTRACT
From April 2023 to May 2024, an unusual epidemic of parvovirus B19 (B19V) infections occurred in France. The number of B19V IgM-positive serologies was four times higher than in the previous epidemic in 2019. Clinical data from emergency networks corroborated this observation. Morbidity and mortality consequences were observed in children through all data sources. In adults, the increase was only observed in laboratory-confirmed data. Physicians and decisionmakers should be informed in order to better prevent, diagnose and manage at-risk patients.